Intravesical immunotherapy with Bacillus Calmette-Guerin (BCG) is commonly used as an adjuvant treatment following transurethral resection of high-risk non-muscle invasive bladder cancer (NMIBC). The completion of treatment maintenance schedules can often require a maximum of three years. Patients successfully complete the entire 3-year BCG maintenance, experience significant advantages, including a 27% decrease progression and a 32% reduction in recurrence risk as compared to intravesical treatment with mitomycin.[1]